Abstract 4042
Background
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with superior disease free (DFS) and overall survival (OS). This association is strongest in triple-negative breast cancer (TNBC). The CPS+EG system, based on pre-treatment clinical (CS) and post-treatment pathologic stage (PS), grade and estrogen receptor status, leads to a refined estimate of prognosis after NACT in all comers and HR+/HER2- (Marmé et al Eur J Cancer 2016). Here we investigate if CPS+EG scoring provides a superior estimate of prognosis in TNBC after NACT to select patients (pts) for post-neoadjuvant therapy.
Methods
We calculated the CPS+EG score for 1795 pts with TNBC from 9 prospective German trials. Pts with missing variables were excluded. 5-year DFS estimates were calculated using the Kaplan Meier method.
Results
Pts who achieved a pCR had a 5-year DFS of 86% (n = 822, 45.8%), whereas pts with residual stage I had a 5-yr DFS of 77.5% (n = 383; 21.3%). CPS+EG score was unable to identify non-pCR pts with a sufficiently good prognosis, to avoid post neoadjuvant therapy. The best prognostic CPS+EG groups (score 1/2) in non-pCR pts had a 5-year DFS of 77.5% and 74.4%, respectively (n = 362; 37.2%). CPS+EG identified a small group (n = 26; 3.2%) at high risk of recurrence despite pCR, mainly based on initial stage (CS+EG score > 3; 5-year DFS 61.4%) that might benefit from additional treatment. However, prognosis of pts with a CPS+EG score of 3 (5-year DFS: 64%), could be further discriminated by pCR (5-year DFS: 83.9% vs 49.7%). Detailed results are presented in the Table.Table:
182PD
pathologic stage: All patients | CPS+EG: All patients | CPS+EG: non-pCR patients | CPS+EG: pCR patients | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PS (N = 1795) | 5-year DFS rate* | 95% CI | N | % | CPS-EG (N = 1795) | 5-year DFS rate* | 95% CI | N | % | CPS-EG (N = 973) | 5-year DFS rate* | 95% CI | N | % | CPS-EG (N = 822) | 5-year DFS rate* | 95% CI | N | % | ||||
0 | 0.86 | 0.84 | 0.89 | 822 | 45.8 | 0 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0 | 0.00 | 0.00 | 0.00 | 0 | 0 |
I | 0.78 | 0.73 | 0.82 | 383 | 21.3 | 1 | 0.83 | 0.77 | 0.89 | 189 | 10.5 | 1 | 0.78 | 0.68 | 0.87 | 88 | 9.0 | 1 | 0.88 | 0.81 | 0.95 | 101 | 12.3 |
IIA | 0.49 | 0.43 | 0.55 | 292 | 16.3 | 2 | 0.84 | 0.81 | 0.86 | 761 | 42.4 | 2 | 0.74 | 0.69 | 0.80 | 274 | 28.2 | 2 | 0.89 | 0.86 | 0.92 | 487 | 59.2 |
IIB | 0.39 | 0.29 | 0.50 | 89 | 5.0 | 3 | 0.64 | 0.59 | 0.69 | 497 | 27.7 | 3 | 0.50 | 0.44 | 0.56 | 289 | 29.7 | 3 | 0.84 | 0.78 | 0.89 | 208 | 25.3 |
IIIA | 0.24 | 0.15 | 0.33 | 109 | 6.1 | 4 | 0.41 | 0.34 | 0.47 | 252 | 14.0 | 4 | 0.38 | 0.32 | 0.45 | 226 | 23.2 | 4 | 0.61 | 0.42 | 0.81 | 26 | 3.2 |
IIIB | 0.19 | 0.02 | 0.36 | 21 | 1.2 | 5 | 0.16 | 0.07 | 0.25 | 71 | 4.0 | 5 | 0.16 | 0.07 | 0.25 | 71 | 7.3 | 5 | 0.00 | 0.00 | 0.00 | 0 | 0.0 |
IIIC | 0.12 | 0.04 | 0.20 | 79 | 4.4 | 6 | 0.00 | 0.00 | 0.00 | 25 | 1.4 | 6 | 0.00 | 0.00 | 0.00 | 25 | 2.6 | 6 | 0.00 | 0.00 | 0.00 | 0 | 0.0 |
Conclusions
pCR remains the strongest and most clinically useful prognostic factor after NACT in TNBC. The CPS-EG score does not add additional information beyond pCR and ypT/N staging in TNBC patients. Other factors than those used beyond staging might be needed in TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
GBG.
Funding
Has not received any funding.
Disclosure
F. Marmé: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Tesaro; Honoraria (self): Novartis; Honoraria (self): Amgen; Honoraria (self): PharmaMar; Honoraria (self): GenomicHealth; Honoraria (self): CureVac; Honoraria (self): EISAI; Honoraria (self): Clovis; Honoraria (self): Celgene. P.A. Fasching: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): BionTech; Honoraria (self): Novartis; Honoraria (self): Roche; Honoraria (self): Pfizer; Honoraria (self): Celgene; Honoraria (self): Daiichi-Sankyo; Honoraria (self): TEVA; Honoraria (self): AstraZeneca; Honoraria (self): Merck Sharp & Dohme; Honoraria (self): Myelo Therapeutics; Honoraria (self): Macrogenics; Honoraria (self): Eisai; Honoraria (self): Puma; Research grant / Funding (institution): Cepheid. A. Schneeweiss: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Molecular Partner; Honoraria (self): Novartis; Honoraria (self), Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self): MSD; Honoraria (self): Tesaro; Honoraria (self): Lilly; Honoraria (self), Travel / Accommodation / Expenses: Pfizer. J. Blohmer: Honoraria (self): Amgen; Honoraria (self): AstraZeneca; Honoraria (self): Genomic Health; Honoraria (self): MSD Oncology; Honoraria (self): Myriad Genetics; Honoraria (self): Novratis/Pfizer; Honoraria (self): Pfizer; Honoraria (self): Rpche; Honoraria (self): Sonoscape. J. Huober: Honoraria (self), Travel / Accommodation / Expenses: Lilly; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Hexal; Honoraria (self): AstraZeneca; Honoraria (self): MSD; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self): Abbie. C. Jackisch: Travel / Accommodation / Expenses: Celgene; Honoraria (self): Roche. T. Link: Honoraria (self): Amgen; Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Non-remunerated activity/ies: Pfizer; Non-remunerated activity/ies: PharmaMar; Non-remunerated activity/ies: Daiichi Sankyo; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Teva; Honoraria (self): Tesaro; Honoraria (self), Non-remunerated activity/ies: Roche. K. Rhiem: Honoraria (self): Tesaro; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer. C. Denkert: Shareholder / Stockholder / Stock options: Sividon Diagnostics; Honoraria (self): Teva; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy: Amgen; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Daiichi Sankyo; Licensing / Royalties: VMScope digital pathology software; Licensing / Royalties: Patent application: EP18209672 - cancer immunotherapy; Licensing / Royalties: Patent application EP20150702464 - therapy response; Licensing / Royalties: Patent application EP20150702464 - therapy response. C. Hanusch: Honoraria (self): Roche; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): Celgene; Honoraria (self): Lilly; Honoraria (self): AstraZeneca. H. Tesch: Honoraria (self): Vifor; Honoraria (self): Roche; Honoraria (self): Amgen. S. Loibl: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Seattle Genetics; Research grant / Funding (institution): Teva; Research grant / Funding (institution): Vifor; Research grant / Funding (institution): PRIME; Research grant / Funding (institution): Daiichi; Licensing / Royalties: EP14153692.0 pending. M. Untch: Honoraria (self), Non-remunerated activity/ies: Abbvie; Honoraria (self), Non-remunerated activity/ies: Amgen GmbH; Honoraria (self), Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Non-remunerated activity/ies: Celgene GmbH; Honoraria (self): BMS; Honoraria (self), Non-remunerated activity/ies: Daiji Sankyo; Honoraria (self), Non-remunerated activity/ies: Eisai GmbH; Honoraria (self), Non-remunerated activity/ies: Janssen Cilag; Honoraria (self), Non-remunerated activity/ies: TEVA Pharmaceuticals Ind Ltd; Honoraria (self), Non-remunerated activity/ies: Sividon Diagnostics; Honoraria (self), Non-remunerated activity/ies: Lilly; Honoraria (self), Non-remunerated activity/ies: MSD Merck; Honoraria (self), Non-remunerated activity/ies: Mundipharma; Honoraria (self), Non-remunerated activity/ies: Myriad Genetics; Honoraria (self), Non-remunerated activity/ies: Odonate; Honoraria (self), Non-remunerated activity/ies: Pfizer GmbH; Honoraria (self): PUMA Biotechnology; Honoraria (self), Non-remunerated activity/ies: Novartis; Honoraria (self), Non-remunerated activity/ies: Roche Pharma AG; Honoraria (self), Non-remunerated activity/ies: Sanofi Aventis Deutschland GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
4132 - Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)
Presenter: Mattea Reinisch
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
5429 - Long-term results of the PACS 04 trial evaluating adjuvant Epirubicin plus Docetaxel in node-positive breast cancer and Trastuzumab in the HER2-positive subgroup
Presenter: Veronique D'Hondt
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
3790 - Tumor size and overall survival in a cohort of young (_40 years), node negative, systemically untreated breast cancer patients; by the PARADIGM study group.
Presenter: Vincent De Jong
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
4332 - Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)
Presenter: Jenny Furlanetto
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
1375 - Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments – a population-based study
Presenter: Nienke De Glas
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
4001 - Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer
Presenter: Per Eystein Lønning
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
3933 - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer
Presenter: Hans Eikesdal
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
1804 - Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancers
Presenter: Tess O'Meara
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
Poster Discussion - Breast cancer, early stage - Invited Discussant 179PD, 180PD and 181PD
Presenter: Laura Biganzoli
Session: Poster Discussion - Breast cancer, early stage
Resources:
Slides
Webcast